The pooled data from the seven trials dedicated to NSCLC showed a statistically significant better overall response rate (ORR) in patients with PD‐L1‐positive tumors compared to those with PD‐L1‐negative tumors 67. Here, CD274 is linked to non-small cell lung carcinoma.